文献速递消化系统肿瘤支持与姑息治疗

增强工程化T细胞抗肿瘤效力与特异性的新策略

Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.
PubMed 文献 · Cancer Discov · 2018-06-07

该研究开发了一种基于三种新型嵌合受体的T细胞工程化方法,使T细胞仅在肿瘤部位响应特定表达模式。以胰腺癌为模型,工程化T细胞识别前列腺干细胞抗原、TGFβ和IL4,并在肿瘤部位产生强效抗肿瘤作用,同时抵抗免疫抑制性细胞因子。

要点

  • 三联嵌合受体使T细胞仅在肿瘤微环境激活,减少脱靶毒性。
  • 工程化T细胞对TGFβ和IL4的免疫抑制具有抵抗作用。
  • 该策略可扩展至PD-L1、IL10和IL13等其他肿瘤部位抑制分子。

核心结论

  • 通过组合识别肿瘤相关抗原和肿瘤微环境因子的嵌合受体,可增强T细胞抗肿瘤效力并提高安全性。

研究设计与样本

  • 概念验证研究,以胰腺癌为模型,开发并测试表达三种新型嵌合受体的工程化T细胞。

主要发现

  • 工程化T细胞识别前列腺干细胞抗原、TGFβ和IL4,其内结构域提供激活、共刺激和细胞因子支持信号。
  • 工程化T细胞在肿瘤部位产生强效抗肿瘤效应,并抵抗TGFβ和IL4的免疫抑制。

临床怎么用

  • 该策略为工程化T细胞提供了一种提高肿瘤特异性和克服免疫抑制的思路,可扩展至其他抑制分子。

局限性

  • 原文未报告临床样本量、疗效数值及统计显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The adoptive transfer of chimeric antigen receptor (CAR)-modified T cells has produced tumor responses even in patients with refractory diseases. However, the paucity of antigens that are tumor selective has resulted, on occasion, in "on-target, off-tumor" toxicities. To address this issue, we developed an approach to render T cells responsive to an expression pattern present exclusively at the tumor by using a trio of novel chimeric receptors. Using pancreatic cancer as a model, we demonstrate how T cells engineered with receptors that recognize prostate stem cell antigen, TGFβ, and IL4, and whose endodomains recapitulate physiologic T-cell signaling by providing signals for activation, costimulation, and cytokine support, produce potent antitumor effects selectively at the tumor site. In addition, this strategy has the benefit of rendering our cells resistant to otherwise immunosuppressive cytokines (TGFβ and IL4) and can be readily extended to other inhibitory molecules present at the tumor site (e.g., PD-L1, IL10, and IL13).Significance: This proof-of-concept study demonstrates how sophisticated engineering approaches can be utilized to both enhance the antitumor efficacy and increase the safety profile of transgenic T cells by incorporating a combination of receptors that ensure that cells are active exclusively at the tumor site. Cancer Discov; 8(8); 972-87. ©2018 AACR.See related commentary by Achkova and Pule, p. 918This article is highlighted in the In This Issue feature, p. 899.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Sukumaran S, Watanabe N, Bajgain P, et al. Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov. 2018. PMID: 29880586. doi:10.1158/2159-8290.CD-17-1298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。